Background & aims: Long-term liver-related complications of Gaucher disease (GD) include cirrhosis, portal hypertension and hepatocellular carcinoma. Although liver fibrosis is the main determinant of adverse liver-related clinical outcomes, it has rarely been evaluated in previously published cohorts of GD patients. We aimed at: assessing the prevalence of significant liver fibrosis in a cohort of patients with type 1 GD; identifying its predictors among GD-related variables, enzyme replacement therapy (ERT) and metabolic features. Methods: 37 adult type 1 GD patients from two Italian academic referral centers were prospectively submitted to vibration controlled transient elastography (Fibroscan®); significant fibrosis was defined as liver stiffness ≥7 kPa. Results: Median liver stiffness was 4.6 [3–15.1] kPa and 7 patients (19%) had significant fibrosis. Significant fibrosis was associated with splenectomy (p =.046) and with scores (DS3: p =.002; SSI: p =.026) and biomarkers (ACE: p =.016; HDL cholesterol: p =.004) of GD severity. Length of ERT was significantly lower in GD patients with significant fibrosis. In the subgroup of 29 patients who were on stable ERT for at least 24 months, further to splenectomy, GD severity and non-N370S GBA1 genotypes, also diastolic blood pressure, BMI and the number of metabolic syndrome (MetS) components emerged as factors significantly associated with significant fibrosis. Conclusions: Significant fibrosis is present in a remarkable proportion of adult type 1 GD patients. Splenectomy, GD severity and GBA1 genotypes are major GD-related predictors of liver fibrosis. Length of ERT is inversely correlated with liver disease in GD patients, suggesting a beneficial effect of ERT on liver fibrosis. However, GD patients on stable ERT should be monitored for metabolic complications, since MetS features may enhance liver disease progression despite optimal GD control.

Prevalence and predictors of liver fibrosis evaluated by vibration controlled transient elastography in type 1 Gaucher disease / Nascimbeni, Fabio; Cassinerio, Elena; Dalla Salda, Annalisa; Motta, Irene; Bursi, Serena; Donatiello, Salvatore; Spina, Vincenzo; Cappellini, Maria Domenica; Carubbi, Francesca. - In: MOLECULAR GENETICS AND METABOLISM. - ISSN 1096-7192. - 125:1-2(2018), pp. 64-72. [10.1016/j.ymgme.2018.08.004]

Prevalence and predictors of liver fibrosis evaluated by vibration controlled transient elastography in type 1 Gaucher disease

Nascimbeni, Fabio;Dalla Salda, Annalisa;Bursi, Serena;Donatiello, Salvatore;Spina, Vincenzo;Cappellini, Maria Domenica;Carubbi, Francesca
2018

Abstract

Background & aims: Long-term liver-related complications of Gaucher disease (GD) include cirrhosis, portal hypertension and hepatocellular carcinoma. Although liver fibrosis is the main determinant of adverse liver-related clinical outcomes, it has rarely been evaluated in previously published cohorts of GD patients. We aimed at: assessing the prevalence of significant liver fibrosis in a cohort of patients with type 1 GD; identifying its predictors among GD-related variables, enzyme replacement therapy (ERT) and metabolic features. Methods: 37 adult type 1 GD patients from two Italian academic referral centers were prospectively submitted to vibration controlled transient elastography (Fibroscan®); significant fibrosis was defined as liver stiffness ≥7 kPa. Results: Median liver stiffness was 4.6 [3–15.1] kPa and 7 patients (19%) had significant fibrosis. Significant fibrosis was associated with splenectomy (p =.046) and with scores (DS3: p =.002; SSI: p =.026) and biomarkers (ACE: p =.016; HDL cholesterol: p =.004) of GD severity. Length of ERT was significantly lower in GD patients with significant fibrosis. In the subgroup of 29 patients who were on stable ERT for at least 24 months, further to splenectomy, GD severity and non-N370S GBA1 genotypes, also diastolic blood pressure, BMI and the number of metabolic syndrome (MetS) components emerged as factors significantly associated with significant fibrosis. Conclusions: Significant fibrosis is present in a remarkable proportion of adult type 1 GD patients. Splenectomy, GD severity and GBA1 genotypes are major GD-related predictors of liver fibrosis. Length of ERT is inversely correlated with liver disease in GD patients, suggesting a beneficial effect of ERT on liver fibrosis. However, GD patients on stable ERT should be monitored for metabolic complications, since MetS features may enhance liver disease progression despite optimal GD control.
2018
11-ago-2018
125
1-2
64
72
Prevalence and predictors of liver fibrosis evaluated by vibration controlled transient elastography in type 1 Gaucher disease / Nascimbeni, Fabio; Cassinerio, Elena; Dalla Salda, Annalisa; Motta, Irene; Bursi, Serena; Donatiello, Salvatore; Spina, Vincenzo; Cappellini, Maria Domenica; Carubbi, Francesca. - In: MOLECULAR GENETICS AND METABOLISM. - ISSN 1096-7192. - 125:1-2(2018), pp. 64-72. [10.1016/j.ymgme.2018.08.004]
Nascimbeni, Fabio; Cassinerio, Elena; Dalla Salda, Annalisa; Motta, Irene; Bursi, Serena; Donatiello, Salvatore; Spina, Vincenzo; Cappellini, Maria Do...espandi
File in questo prodotto:
File Dimensione Formato  
prevalence and predictors Mol Genet Metab 2018.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 594.88 kB
Formato Adobe PDF
594.88 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Prevalence...accepted article pre-print version YMGME_6390_edit_report (1).pdf

Open access

Tipologia: Versione dell'autore revisionata e accettata per la pubblicazione
Dimensione 308.32 kB
Formato Adobe PDF
308.32 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1179841
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 17
social impact